SpeeDx and Nepean Hospital Awarded Federal Funding for Viral Respiratory Biomarker Test
3.9.2020 06:34:00 EEST | Business Wire | Press release
SpeeDx Pty. Ltd., a developer of innovative molecular diagnostic solutions, in partnership with researchers from Nepean Blue Mountains Local Health District’s (NBMLHD) Nepean Hospital Intensive Care Unit were awarded funding through the MTPConnect Biomedical Translation Bridge (BTB) program. Funds will support the commercialisation of a respiratory virus host response test – a rapid-response assay to enhance current COVID-19 management activities and future viral pandemic preparedness.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20200902005970/en/
Utilising newly patented InSignia(TM) technology that enhances the measurement of gene expression, the test will be a rapid, high-throughput tool to support risk-based stratification of patients presenting with respiratory viral illness, including COVID-19. (photo: Sara Eshleman/Wikimedia Commons)
SpeeDx are adapting the NBMLHD laboratory developed test that targets a key genetic marker that is uniquely expressed in response to respiratory virus infection, with levels of the marker correlated with disease progression.1,2 Utilising newly patented In SigniaTM technology that enhances the measurement of gene expression, the commercial test will be a rapid, high-throughput tool to support risk-based stratification of patients presenting with respiratory viral illness, including COVID-19.
“The MTPConnect BTB funding will be instrumental in advancing our commercialisation process and supporting the tight timelines we are setting in order to bring this important product to market” said Colin Denver, SpeeDx CEO.
Delivered by MTPConnect, the Australian Government's BTB program is a $22.3 million MRFF initiative that provides up to $1 million in matched funding to nurture the translation of new therapies, technologies and medical devices through to proof of concept to turn innovative medical ideas into reality.
About SpeeDx
Founded in 2009, SpeeDx is an Australian-based private company with subsidiary offices in Austin and London, and distributors across Europe. SpeeDx specializes in molecular diagnostic solutions that go beyond simple detection to offer comprehensive information for improved patient management. Innovative real-time polymerase chain reaction (qPCR) technology has driven market-leading multiplex detection and priming strategies. Product portfolios focus on multiplex diagnostics for sexually transmitted infection (STI), antibiotic resistance markers, and respiratory disease. For more information on SpeeDx please see: https://plexpcr.com
About Nepean and Blue Mountains Local Health District
Nepean Blue Mountains Local Health District is well placed to draw on over 100 years of continuously caring for the community, conducting research and delivering innovation. The Nepean Hospital Intensive Care Unit is part of NBMLHD’s 5,700-strong staff. Being on the frontline of health means NBMLHD has a focus on practical solutions that deliver maximum impact to the health and wellbeing of patients and their families.
References
- Tang BM et al. Eur Respir J. 2017 Jun 15;49(6):1602098.
- https://www.smh.com.au/national/covid-19-blood-test-to-predict-which-patients-will-need-the-most-care-20200406-p54hja.html
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20200902005970/en/
Contact information
SpeeDx
Australia, New Zealand and Europe
Madeline O’Donoghue - SpeeDx
+61 406 582 808
United States
Rick Roose - RCI Healthcare Public Relations
+1 415 202 4445
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Bureau Veritas Confirms LEAP | 28 Ambition, Upgrades Total Revenue Growth to Double-Digit in 2027 – 2028 1 and Targets EUR1 Billion Revenue in AI-Driven Markets and Services by 203022.9.2026 08:30:00 EEST | Press release
Bureau Veritas (BOURSE:BVI): CAPITAL MARKETS DAY 2026 Today, Bureau Veritas hosts its Capital Markets Day. The Company will present an update on the progress of its LEAP | 28 strategy, building on three years of successful execution. › 2024-2026 achievements: Proven track record: mid-to-high single-digit organic revenue growth (7-8%) delivered across 2023–2026e2, with 115 basis points of adjusted operating margin improvement3; Portfolio transformation on track: c. 21.0% of the portfolio rotated since LEAP | 28 launch, with EUR1.2 billion of revenue acquired, sold or to be exited through 24 acquisitions, 4 divestments and 1 exit; New operating model: the active portfolio management delivered allowed the Company to create a new operating model that simplifies its growth algorithm. Combined with a simplified organization with four divisions and ten Product Lines, it sharpens Bureau Veritas’ position as a focused multi-specialist Company; Driving growth and profitability: through Portfolio
OPM Biosciences Launches Integrated Cell Culture Media-to-Manufacturing Platform for Biosimilar Development22.9.2026 08:00:00 EEST | Press release
OPM Biosciences, a cell culture media and bioprocess solutions company, today announced two new offerings that extend its OPM-CHO™ platform into biosimilar development and manufacturing: the Biosimilar Media Optimization Service and the Sureness™ Biosimilar Platform. Cell culture media can significantly influence cell growth, productivity, and critical quality attributes (CQAs), making media strategy an important component of biosimilar process development. OPM-CHO, the company’s portfolio of chemically defined cell culture media for CHO-based biomanufacturing, has supported more than 390 molecules in clinical and commercial stages worldwide, including biosimilars. Across 35 side-by-side evaluations, OPM-CHO media delivered an average titer improvement of 96% over each program’s original media combinations*. In separate internal studies, OPM-CHO media demonstrated lot-to-lot variability below 5%.* As patent expirations create new opportunities for biosimilar development, achieving a pr
H2SITE Secures €3.4 Million (NOK 39.1 million) in Enova Funding to Scale Onboard Ammonia-To-Power for Commercial Maritime Applications22.9.2026 07:00:00 EEST | Press release
H2SITE has secured €3.4 million (NOK 39.1 million) in funding from Enova for HydraNord Power, a project that will develop and validate a commercial-scale onboard ammonia-to-power system for the maritime sector. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921324898/en/ Enova is one of the Norwegian government's primary instruments for accelerating the country's climate and energy transition. Its primary responsibility is to manage the Climate and Energy Fund on behalf of the Norwegian government. For H2SITE, Enova’s support is a major milestone in the commercialisation of its onboard ammonia cracking technology, enabling the company to scale from proven maritime demonstrations to replicable commercial solutions for the global shipping industry. Led by H2SITE, HydraNord Power will convert ammonia into high-purity hydrogen directly onboard vessels. The system will produce up to one tonne of hydrogen per day and supply mar
EcoOnline Recognised as a Leader in Verdantix Green Quadrant: EHS Software 2026 for Third Time21.9.2026 19:43:00 EEST | Press release
EcoOnline, the global provider of software that transforms how organisations protect people and the planet, has been recognised for the third consecutive time as a Leader in the independent Verdantix Green Quadrant: EHS Software 2026 report, with market-leading strength in Safety Management. The assessment evaluated leading vendors of environmental, health and safety software vendors across a range of capabilities and customer buying signals. Verdantix recognised EcoOnline’s strength in the areas organisations rely on to protect workers every day: Safety Management, Chemicals Management, AI-enabled Training and Contractor Safety. It reflects the changing needs of EHS buyers, who are increasingly looking for integrated platforms that connect everyday safety with broader operational risk and crisis preparedness. EcoOnline achieved the highest score for Safety Management, reflecting the breadth of the platform’s capabilities across the processes organisations use to identify, mitigate, ma
rhode Announces the Return of Limited Edition Favorites and New Exclusives at Sephora Across Europe and the U.K.21.9.2026 16:00:00 EEST | Press release
rhode, the beauty brand founded by Hailey Rhode Bieber and part of e.l.f. Beauty (NYSE: ELF), has announced that two community-favorite Peptide Lip Tints and a new Sephora-exclusive bag will launch at Sephora across Europe and the U.K. to celebrate the brand’s launch into Sephora in Europe on September 30, 2026. These items will join the brand’s assortment of high-performance skincare and hybrid makeup. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260921199856/en/ rhode announces the return of limited edition favorites and new exclusives at Sephora across Europe and the U.K. To mark the occasion with Sephora across Europe and the U.K., rhode is offering early access to purchase fan-favorite, previously limited edition Peptide Lip Tint in Pretzel at Sephora in Europe and the U.K. on the brand’s launch date September 30, before the product joins rhode’s permanent assortment globally on rhodeskin.com on October 1 and at all r
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom